Azadeh Namakydoust
Merck & Co., Inc., Rahway, NJ, USA (United States)
ORCID: 0000-0002-5252-5648Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Papers
Driven by 7 papers. Top paper: “Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study”.
Jonathan T. Yang, Juber Patel, Annemarie F. Shepherd, Juliana Eng, Randy Yeh +44 more
Hira Rizvi, Isabel R. Preeshagul, Jacklynn V. Egger, David Hoyos, Chai Bandlamudi +26 more
Emily S. Lebow, Randy Yeh, Jeeban Paul Das, Azadeh Namakydoust, Paul K. Paik +67 more
Elena N. Petre, Ken Zhao, Vlasios S. Sotirchos, Azadeh Namakydoust, Amgad M. Moussa +5 more
Pang‐Dian Fan, Besnik Qeriqi, Azadeh Namakydoust, Bobby Daly, Linda S. Ahn +9 more
Emily S. Lebow, Yonina R. Murciano‐Goroff, Gowtham Jayakumaran, Ronglai Shen, A. Rose Brannon +15 more
Prasad S. Adusumilli, Michael Offin, Stephen B. Solomon, Etay Ziv, Sara A. Hayes +22 more